MSB Mesoblast Ltd.

Randomized Controlled Phase 3 Trial of Remestemcel-L for Reduced Mortality in COVID-19 Acute Respiratory Distress Syndrome Surpasses 50% Enrollment

Randomized Controlled Phase 3 Trial of Remestemcel-L for Reduced Mortality in COVID-19 Acute Respiratory Distress Syndrome Surpasses 50% Enrollment
EN
13/10/2020

Underlying

MSBMesoblast Ltd.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mesoblast Ltd.

 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Mesoblast to Host R&D Day on April 8, 2026

Mesoblast to Host R&D Day on April 8, 2026 NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast’s senior leadership team and from key opinion leaders. The event will include discussions regarding the company’s corporate strategy, successful commercialization of its flagship product Ryoncil®, and its rob...

March 17, 2026 1 EN
 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affa...

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast’s medical affairs organization, fostering clinical collaborations and spearheading investigator-initia...

March 11, 2026 1 EN
Free Trial
MSB MESOBLAST LTD.

Mesoblast Ltd: 1 director

A director at Mesoblast Ltd bought 11,070,522 shares at 1.479USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

03/10/26 March 10, 2026 1 EN
 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Ryoncil® Profits Underpinning Substantial Growth Pipeline

Ryoncil® Profits Underpinning Substantial Growth Pipeline Financial Results and Operational Update for Half-Year Ended December 31, 2025 NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 (H1 FY2026). FINANCIAL HIGHLIGHTS FOR H1 FY20261 Performance driven by successful commercial launch of Ryoncil® Total revenue of US$51.3 million (A$78.3 million),2 up from US$3.2 million.Successf...

February 27, 2026 1 EN
 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Mesoblast Financial Results and Corporate Update Webcast

Mesoblast Financial Results and Corporate Update Webcast NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025. The webcast will begin at 5.00pm EST, Thursday, February 26; 9.00am AEDT, Friday, February 27, 2026. It can be accessed via: The archived webcast will be available on the Investor page of the Company’s website: About Mesoblast Mesoblast (the Company) is ...

February 20, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch